echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > How much do you know about the related factors of cerebral microhemorrhage in patients with dominant hereditary Alzheimer's disease?

    How much do you know about the related factors of cerebral microhemorrhage in patients with dominant hereditary Alzheimer's disease?

    • Last Update: 2021-04-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Cerebral microhemorrhages (CMHs) are more common in the elderly, especially in patients with Alzheimer's disease.

    These hemorrhages are usually related to hypertension, Alzheimer's disease (AD)-related cerebral amyloid angiopathy (CAA), and Aβ-modified therapy treated amyloid-related imaging abnormality (ARIA) AD.

    Therefore, in order to study the inherent clinical risks associated with CMHs and determine the characteristics of high-risk individuals with ARIA-H abnormalities, American scholar Nelly Joseph-Mathurin analyzed 511 families from 19 DIAN locations with dominant inherited AD (DIAD).
    Participants were evaluated.

    The research results were published in the recent Neurology.

    Yimaitong compiles and organizes, please do not reprint without authorization.

     Research Introduction The researchers divided 511 participants into gene mutation carrier group (n=310) and non-carrier group (n=201), and performed neuroimaging examinations on them to evaluate the gradient echo MRI sequence and nerve of CMHs.
    Psychological and clinical results.

    Cross-sectional and longitudinal analyses were used to assess the association between CMHs and neuroimaging and clinical disease markers.

     Main findings ➤ The clinical assessment based on the Clinical Dementia Assessment Scale (CDR) and the Clinical Dementia Assessment Scale (CDR-SB) did not differ between the presence or absence of CMHS carriers, while the comprehensive cognitive measurement assessment showed that CMHs carriers The cognitive impairment was more severe than that of non-CMHs and non-carriers (0.
    31 vs.
    1.
    67 vs.
    1.
    05), and the difference was statistically significant (P<0.
    001).

     ➤ Of the 511 participants, 32 (6.
    3%) participants had CMHs at baseline.Of 310 carriers, 26 (8.
    4%) had CMHs, and out of 201 non-carriers, only 6 (3.
    0%) had CMHs.

    The prevalence of CMH in asymptomatic carriers was 3.
    0%, and the prevalence of CMH in symptomatic carriers was 18.
    3%.

     ➤ Multivariate logistic regression analysis found that carriers are more likely to develop CMH than non-carriers (OR = 3.
    575, 95%CI: 1.
    499, 9.
    904).

    Age and diastolic blood pressure were significantly correlated with the risk of CMHS (OR = 1.
    071, 95%CI: 1.
    034, 1.
    110; OR = 1.
    068, 95%CI: 1.
    030, 1.
    108).

    The APOE e4 status has nothing to do with the prevalence or incidence of CMHS.

    Over time, the presence of ≥2 CMHs was significantly associated with the risk of continuing to promote CMH (8.
    95 ± 10.
    04 per year).

     Conclusion The results of this cross-sectional and longitudinal analysis describe the factors associated with microbleeds in the DIAD population.

    CMHs are part of the underlying disease process of DIAD and are significantly associated with dementia.

    These findings have important implications for the selection and monitoring of DIAD populations participating in clinical trials.

     Yimaitong compiled from: Joseph-Mathurin N, Wang G, Kantarci K, et al.
    Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease[J].
    Neurology, 2021,96(12):e1632-e1645.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.